Cases & Deals

sanofi-aventis acquires TargeGen for $560 million

Clients sanofi-aventis S.A.

Jones Day advised sanofi-aventis S.A. in reaching a $560 million merger agreement with TargeGen Inc., a privately held US biopharmaceutical company developing small molecule kinase inhibitors for the treatment of certain forms of leukemia, lymphoma and other hematological malignancies and blood disorders. In addition to M&A representation, Jones Day provided tax, benefits and IP advice regarding this transaction.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.